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$7,098 among those switching, discontinuing or persisting,
respectively. The costs associated with switching and discontinu-
ing treatment were signiﬁcantly higher (p < 0.0001) than with
persistence, even when adjusting for patient characteristics, MS
drug use, and medical costs during the six months preceding
treatment start. Hospitalizations were the primary source of the
increased costs (means of $2597, $2191, and $1160 for switch-
ing, discontinuing, and persisting, respectively). CONCLUSION:
One year after treatment initiation with index drug, over a third
of MS patients discontinue or switch ABCR treatment and incur
higher hospitalization related medical costs than those persisting
with therapy. Discontinuation or switches due to potential sub-
optimal treatment and subsequent hospitalizations may be driven
by disease relapses, suggesting a need for more highly effective
MS therapies.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin in
the treatment of ﬁbromyalgia (FM) from a US perspective.
METHODS: We developed a micro-simulation model to assess
the cost-effectiveness of pregabalin therapy (450 mg/d) in a hypo-
thetical cohort of patients with moderate or worse pain due to
FM. The model simulates pain experience on a weekly basis over
14 weeks, using data from a randomized, placebo-controlled
clinical trial. Pain levels were estimated using an 11-point
numeric rating scale; moderate or worse pain was assumed to be
a pain score 4. Health-state utilities were assigned based on
estimated pain level, using published values for the Health Utili-
ties Index [HUI]—Mark II. Costs of drug therapy only were
considered. Cost-effectiveness of pregabalin therapy was consid-
ered alternatively versus placebo and no therapy, the latter
because pregabalin is the only drug currently indicated for the
treatment of FM. Cost-effectiveness was expressed in terms of
both incremental cost per additional day without moderate or
worse pain and incremental cost per quality-adjusted life-year
(QALY) gained. RESULTS: In comparison with no treatment,
pregabalin therapy was estimated to yield an average of 29.4
additional days without moderate or worse pain over 14 weeks,
and a gain of 0.019 QALYs. Corresponding estimates for the
comparison with placebo were 11.4 additional days without
moderate or worse pain, and 0.009 additional QALYs. Assuming
a daily cost of therapy of $3.30, the incremental cost (95% CI) of
pregabalin therapy per additional day without moderate or
worse pain was $11 ($9, $14) versus no treatment, and $32 ($18,
$72) versus placebo. Corresponding estimates of the incremental
cost per QALY gained were $39,266 ($27,167, $57,269)
and $17,220 ($15,289, $20,153), respectively. CONCLUSION:
In patients with moderate or worse pain due to FM, the
cost-effectiveness of pregabalin falls within accepted published
thresholds.
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OBJECTIVE: Studies in patients with multiple sclerosis (MS)
have shown that disease-modifying drugs (DMDs) lower the
frequency and severity of relapses and slow disease progression.
The clinical and economic consequences of regimens involving
switches between DMDs have not been studied fully. The fol-
lowing analysis sought to examine clinical and economic out-
comes in MS patients who switch from one of the two leading
DMDs in the United States (IFNb-1a intramuscular [IM] and
glatiramer acetate [GA]) to a high-dose high-frequency (HDHF)
interferon beta (IFNb-1b subcutaneous [SC], IFNb-1a SC) or
natalizumab, a second-line agent. METHODS: A previously
published pharmacoeconomic model was modiﬁed to evaluate
switching scenarios and estimate total cost of MS care and the
number of relapses avoided over a four year period. The model
assumes that switches from the ﬁrst agent occurred at the end of
the ﬁrst year and that the second agent is continued through the
end of the four year period. Clinical data inputs were derived
from Class I clinical trials. The costs of relapses and disability
steps were based on published literature, and drug prices were
obtained from the Red Book. Relative cost-effectiveness
between switching scenarios was compared by calculating the
cost per relapse avoided over the four year time frame.
RESULTS: The cost of avoiding one relapse in patients switch-
ing from IFNb-1a IM to IFNb-1a SC or IFNb-1b SC was
$84,401 and $87,090, respectively. The most costly switch was
from IFNb-1a IM to natalizumab ($104,568 per relapse
avoided). Switching from GA to IFNb-1a SC, IFNb-1b SC, or
natalizumab resulted in costs per relapse avoided of $70,822,
$73,511, and $90,989, respectively. CONCLUSION: This
analysis suggests that MS patients switched from IFNb-1a IM
or GA to an HDHF IFNb beneﬁted from the lowest cost to
avoid a relapse.
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OBJECTIVE: Triptans (almotriptan, eletriptan, naratriptan,
rizatriptan, sumatriptan, and zolmitriptan) have become the pre-
ferred migraine therapy in Canada and elsewhere. Currently,
health care decision makers are considering developing a consis-
tent listing policy for triptans in publicly-funded drug plans
across Canada. Compelling evidence on cost-effectiveness of trip-
tans applicable to Canadian health care setting is important in
aiding decision-making process. This study examines the validity
and applicability of available evidence of cost-effectiveness
studies of triptans to the Canadian health care system.
METHODS: Cost-effectiveness studies were obtained by search-
ing PubMed and the Cochrane Library and cross-searching
BIOSIS Previews®, EMBASE®, and MEDLINE® databases on
the OVID® search system. A Systematic review was performed
on selected studies. The validity of evidence was assessed by
appraising each study with regards to inclusion of all triptans;
major costs and beneﬁts in the model; resource use in the model;
and use of credible clinical data. RESULTS: Twelve relevant
studies were identiﬁed and reviewed. Of them, two considered
major cost and beneﬁts and resources use but compared only a
few triptans and used unreliable clinical data; eight studies con-
sidered only drug cost with only two out of eight studies com-
pared all triptans using unreliable clinical data; and two studies
considered resource use and major costs/beneﬁts, compared only
a few triptans, and used unreliable clinical data. CONCLUSION:
Available studies on cost-effectiveness of triptans are of limited
utility to Canadian decision markers as they harbour ﬂaws such
as failure to compare all triptans, adoption of less credible clini-
cal estimates, exclusion of major costs/beneﬁts, and failure to
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